Meletios Therapeutics aims to address the urgent and significant unmet medical need for antiviral treatments for current and emerging viral infections by developing innovative small molecules and defective viral genomes.
This French biotech company was created in April 2020 by a team of high level scientists and experienced biotech managers.
One of our first drug candidate has confirmed its broad-spectrum potential in in vitro and in vivo models on the coronavirus family and influenza H1N1, demonstrating a dual antiviral and anti-inflammatory activity. This molecule will now be developed and tested in order to meet regulatory requirements and enter clinical phase II.
Several drug candidates from Meletios portfolio are currently being tested both in vitro and in vivo and will expand our range of antiviral molecules on different RNA viruses. Some of these molecules have already been tested in the clinic for other human diseases, so they will have the following two main advantages: a well-known safety profile and accelerated development.
Meletios Therapeutics’ goal is to become a global leader in the fight against emerging viral infections by developing innovative broad-spectrum therapeutic solutions.
STRENGTHS OF MELETIOS
As far back as we can remember, there has always been a real concern for human communities about epidemics which have been incredibly devastating in the past. And we are nowadays seeing a speeding up of the phenomenon. We are increasingly interconnected and pushing the boundaries of our environment further and further, yielding unknown viruses to come out into the open.
There is thus a real need to anticipate the emergence of new viruses that could lead to globalized epidemics such as COVID-19.
WHY IS THERE A CRITICAL NEED FOR ANTIVIRAL?
To tackle future emerging viruses, every effort must be made to channel epidemics. Vaccines and treatments are two complementary therapeutic strategies.
Vaccines are an essential preventive tool but have the disadvantages of targeting a virus that must be already (well) known and of being uncertain about possible variants. They can be also time-consuming to implement.
An alternative is therefore needed for patients who are already ill in order to treat their symptoms and to resolve the infection from the start of the epidemic. Depending on their mechanism of action, antiviral drugs can be effective against a wide range of viruses and therefore offert significant hope for limiting the impact of pandemics.
We are facing an increasing number of pandemic situations
New viruses are to emerge with a lack of overlap between viruses
Vaccines are mostly efficient against one strain only
Implementation in the population takes long
Viral genome are small and evolve rapidly
It is sometimes impossible
to design a vaccine for a virus
The current antiviral armamentarium is not sufficient to face current and future epidemics
Broad spectrum treatment could be used as soon as a viral pandemic is identified
Antivirals will be efficacious against a large panel of viruses
OUR SCIENTIFIC ADVISORS
meletios’ R&D STRATEGY
We are developing two complementary approaches to combat RNA viruses. Meletios works closely with recognized experts to guide us in each direction.
The first angle is to develop a broad-spectrum antiviral drug by targeting host mechanisms that are hijacked by viruses. In vitro and in vivo proofs of concept were obtained with our small molecules.
The second approach is a disruptive technology from the Institut Pasteur that consists in parasitizing the viral machinery with defective genomes to prevent it from producing new infectious virions.
HOST TARGETTING AGENTS
Host functions hijacked by viruses
– Broad spectrum molecules
– In vitro & vivo proof of concept
– Internal Meletios Development
DEFECTIVE INTERFERING PARTICLES
Defective viral genomes
Parasite of viral machinery
– Disruptive technology
– Originating from a prestigious academic center: The Institut Pasteur
2 March 2022 – License agreement with the Institut Pasteur for a new class of antivirals: Interview – Marco Vignuzzi (Institut Pasteur) x Catherine Martre (Meletios Therapeutics)
The mission is to take charge of the synthesis process and the supply of active ingredients, as well as the formulation and manufacturing of the products in the portfolio, taking into account the regulatory constraints, in order to allow the completion of preclinical studies and the first clinical phases of the products developed by the company in the targeted indications.
Coordination of CMC activities, from the development of the chemical synthesis process, from galenics to industrial scale-up
- Development of the active ingredient synthesis process with partners.
- Process development and scale up.
- Characterization/Analytical Validation API and Drug products.
- Pre-formulation and formulation studies (outsourced).
- Batch generation for toxicity studies and GMP batch for clinical studies
- Follow-up of the production and validation of non-GMP and GMP batches
- Conduct of CMC regulatory activities related to regulatory files
- Follow-up/Drafting of scientific, technical and regulatory files (IMPD, eCTD, IND, NDA)
- Search and evaluation of subcontractors,
- Coordination of subcontractors involved in pharmaceutical development, in compliance with quality and regulatory standards, deadlines and costs
- Management of preclinical and clinical logistics
- Securing the supply of active ingredients
You have a scientific background (Master 2 Industrial Pharmacy / formulation / production processes, Chemical Engineer, PharmD or PhD). You have a solid knowledge of chemistry and galenics (properties of active ingredients, properties of excipients, galenic forms), associated manufacturing processes and regulatory requirements. You have a minimum of 5 years of successful experience related to the missions expected for this position.
You have a taste for challenge and you are motivated to join a young and innovative company. You are autonomous, innovative, have a strong sense of initiative and are attracted by teamwork. You communicate fluently in English, both in writing and orally, and have a sense of priorities and organization.
Permanent contract to be filled immediately. Paris
Contact: Please send your application to firstname.lastname@example.org
You are interested in joining our team? Do not hesitate to submit your application with a cover letter and resume at email@example.com!
Get in touch with us
You are interested in a partnership opportunity, a job or just want to know more about us? We’d like to hear from you. Don’t hesitate to reach us directly!